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in CTLA4 in Cocker spaniels affected with
immune-mediated haemolytic anaemia
Anna J. Threlfall1*, Alisdair M. Boag2, Francesca Soutter3, Barbara Glanemann1, Harriet M. Syme1 and Brian Catchpole3Abstract
Background: Cocker spaniels are predisposed to immune-mediated haemolytic anaemia (IMHA), suggesting that
genetic factors influence disease susceptibility. Dog leukocyte antigen (DLA) class II genes encode major
histocompatibility complex (MHC) molecules that are involved in antigen presentation to CD4+ T cells. Several DLA
haplotypes have been associated with autoimmune disease, including IMHA, in dogs, and breed specific differences
have been identified. Cytotoxic T lymphocyte antigen 4 (CTLA4) is a critical molecule involved in the regulation of
T-cell responses. Single nucleotide polymorphisms (SNPs) in the CTLA4 promoter have been shown to be associated
with several autoimmune diseases in humans and more recently with diabetes mellitus and hypoadrenocorticism in
dogs. The aim of the present study was to investigate whether DLA-DQB1 alleles or CTLA4 promoter variability are
associated with risk of IMHA in Cocker spaniels.
Results: There were a restricted number of DLA-DQB1 alleles identified, with a high prevalence of DLA-DQB1*007:01
in both groups. A high prevalence of DLA-DQB1 homozygosity was identified, although there was no significant
difference between IMHA cases and controls. CTLA4 promoter haplotype diversity was limited in Cocker spaniels,
with all dogs expressing at least one copy of haplotype 8. There was no significant difference comparing haplotypes
in the IMHA affected group versus control group (p = 0.23). Homozygosity for haplotype 8 was common in Cocker
spaniels with IMHA (27/29; 93 %) and in controls (52/63; 83 %), with no statistically significant difference in prevalence
between the two groups (p = 0.22).
Conclusions: DLA-DQB1 allele and CTLA4 promoter haplotype were not found to be significantly associated with
IMHA in Cocker spaniels. Homozygosity for DLA-DQB1*007:01 and the presence of CTLA4 haplotype 8 in Cocker
spaniels might increase overall susceptibility to IMHA in this breed, with other genetic and environmental factors
involved in disease expression and progression.
Keywords: Dog Leukocyte Antigen (DLA), Cytotoxic-T-Lymphocyte-Antigen-4 (CTLA4), Cocker spaniel, Immune
Mediated Haemolytic Anaemia (IMHA)Lay summary
Cocker spaniels are predisposed to developing immune-
mediated haemolytic anaemia (IMHA), where red blood
cells are destroyed by antibodies produced by the im-
mune system. The breed predisposition suggests genetic
susceptibility, and the present study was designed to in-
vestigate whether two different immune response genes
were involved in increasing the risk of IMHA in this* Correspondence: ajthrelfall@rvc.ac.uk
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Mymms, Hatfield AL9 7TA, Hertfordshire, UK
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creativecommons.org/publicdomain/zero/1.0/breed. Dog leukocyte antigen (DLA) class II genes code
for molecules involved in stimulating the immune sys-
tem against foreign and potentially host proteins. Several
studies have shown that some variants of DLA genes can
increase or reduce the risk of developing autoimmune dis-
eases. Cytotoxic T lymphocyte antigen 4 (CTLA4) is a
molecule that acts like a ‘braking system’ for the immune
system. If this does not work properly, the immune system
can become relatively hyperactive. Alterations in the gen-
etic code for this molecule are associated with several dis-
eases in humans and dogs, especially diseases of the
immune system. The aim of this study was to investigatearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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quences are associated with risk of IMHA in Cocker
spaniels.
Limited variability in DLA-DQB1 alleles was identified
in Cocker spaniels and there was no obvious difference
comparing dogs that developed IMHA and those that
did not. CTLA4 diversity was also limited in Cocker
spaniels and there was no significant difference between
the IMHA-affected group and the control group.
DLA-DQB1 and CTLA4 variation was limited in
Cocker spaniels and was not found to be specifically as-
sociated with IMHA. The high prevalence of certain al-
leles might increase the overall breed susceptibility to
IMHA, with other genetic and/or environmental factors
acting as a trigger for the disease to develop.
Background
Immune mediated haemolytic anaemia (IMHA) is a life
threatening disease. It is relatively frequently encoun-
tered in dogs, with an estimated prevalence of 0.2 % [1].
The disease is characterised by production of anti-
erythrocyte antibodies, with or without involvement of
complement, and subsequent destruction of red blood
cells, either within the circulation (intravascular haemoly-
sis) or in the liver and spleen (extravascular haemolysis).
Production of anti-erythrocyte antibodies occurs spontan-
eously in approximately 65–75 % of cases (primary or
idiopathic IMHA) [2–6], or can occur secondary to alter-
ations in erythrocyte antigenicity as a result of a variety of
factors (secondary IMHA). Risk factors for secondary
IMHA include exposure to drugs/toxins, neoplasia, infec-
tions and systemic immune-mediated disorders. There are
breed differences in susceptibility to IMHA in dogs, with
the Cocker spaniel being overrepresented in several stud-
ies [3, 4, 6–10]. The difference in prevalence between
breeds suggests that genetic factors might play a role in
determining susceptibility to IMHA in dogs.
MHC class II molecules are central to the presentation
of antigen for recognition by T lymphocytes: in humans
their encoding genes (HLA-D) have been frequently im-
plicated in the pathogenesis of autoimmune diseases
[11]. MHC class II variability has been studied exten-
sively in human medicine, and certain human leukocyte
antigen (HLA) haplotypes have been found to increase
(HLA-DR3 and DR4) or decrease (HLA-DR2) the rela-
tive risk for developing specific autoimmune diseases
[12–15]. Specifically, HLA-DR3 is associated with Graves’
disease in humans; the frequency of DR3 in Graves’ dis-
ease patients was 40–55 % compared to 15–30 % in the
general population, resulting in a relative risk for people
with HLA-DR3 of 3.4 [12]. More recently, it has been
demonstrated that HLA-DR3 is the primary HLA class II
allele responsible for susceptibility to type 1 diabetes and
autoimmune thyroid disease in families in which bothdiseases cluster [13]. Similarly, almost all patients with
type I diabetes express HLA-DRA 3 and/or HLA-DRA4,
and HLA-DR2 is strongly protective; individuals carrying
HLA-DR2, even in association with one of the susceptibil-
ity alleles, rarely develop diabetes [15]. Some HLA alleles
predispose to multiple diseases (HLA-DRA3/4), although
there are many HLA allelic associations with individual
diseases [14]. The genetic basis of autoimmune haemolytic
anaemia is poorly characterised in humans, with limited
data available, although there have been conflicting re-
ports of association with HLA-A1, B7 and B8 [16].
Various associations have been identified with the dog
leukocyte antigen (DLA) complex and autoimmune dis-
ease, including systemic lupus erythematosus (SLE) [17],
hypoadrenocorticism [18, 19], canine rheumatoid arth-
ritis [20], hypothyroidism [21–23], diabetes mellitus [24],
necrotising meningoencephalitis [25], anal furunculosis
[26] and canine IMHA [27]. Specifically the presence of
DQB1*007:01 was associated with IMHA and DQB1*
020:01 associated with a decreased risk [27].
In humans, genome wide association studies (GWAS)
and candidate gene studies have identified associations
with polymorphisms in CTLA4 on chromosome 2 and
several immune mediated diseases, including type I dia-
betes, Graves’ disease, Hashimoto’s thyroiditis, hypoadre-
nocorticism, rheumatoid arthritis and multiple sclerosis
[28–32]. Two SNPs in particular have been associated
with human type 1 diabetes (+49A/G SNP in exon one
and -318C/T SNP found in the promoter region) [33–35].
CTLA4 (CD152) is a cell surface receptor expressed
only on primed T lymphocytes and regulatory-T cells.
CTLA4 binds CD80/86 ligands, leading to inhibition of
T cell activity. CTLA4 is the most important T-cell in-
hibitory receptor; mice lacking CTLA4 die at a young
age due to uncontrolled proliferation of lymphocytes in
multiple organs [36].
In dogs, sequencing of the canine CTLA4 gene has
revealed a remarkable amount of variation within the
1.5 kbp promoter region, in which 20 SNPs and three in-
sertion/deletions (indels) have been identified, with a total
of 17 haplotypes being assigned [37, 38]. In dogs, certain
CTLA4 promoter polymorphisms and haplotypes have
been associated with both increased and decreased sus-
ceptibility to diabetes in multiple breeds [37], and to
hypoadrenocorticism in Cocker spaniels [38] and Springer
spaniels [39]. Haplotypes 3 and 12 were noted to increase
the risk of hypoadrenocorticism in Cocker spaniels (Odds
Ratio [OR] = 4.0 and 7.76 respectively) and haplotype 8
was found to decrease the risk (OR = 0.22) [38].
A recent study suggested that HLA and CTLA4 poly-
morphisms might confer a synergistic risk in the suscep-
tibility to Grave’s disease in humans [40]. A possible link
between HLA polymorphisms and expression of CTLA4
has also been suggested in human type 1 diabetes [41],
Table 1 DLA-DQB1 allele frequency in Cocker spaniels with (cases)
and without (controls) IMHA
DQB1 allele Cases
(2n = 58)
Cases
(frequency)
Controls
(2n = 126)
Controls
(frequency)
P value
DQB1*002:01 1 0.017 2 0.016 1.000
DQB1*007:01 41 0.707 81 0.643 0.502
DQB1*lk007cs 2 0.034 5 0.040 1.000
DQB1*012:01 1 0.017 4 0.032 1.000
DQB1*013:02 0 0 1 0.008 1.000
DQB1*013:03 2 0.034 2 0.016 0.600
DQB1*020:01 7 0.121 24 0.190 0.293
DQB1*020:02 1 0.017 3 0.024 1.000
DQB1*021:01 1 0.017 2 0.016 1.000
DQB1*023:01 1 0.017 0 0 0.315
DQB1*08:01:1 1 0.017 2 0.016 1.000
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sociation between HLA and CTLA4. Given the likely in-
volvement of CTLA4 in the pathogenesis of canine
autoimmune diseases, the variation in DQB1 alleles be-
tween Cocker spaniels with and without IMHA [27],
and the possible association between HLA and CTLA4
polymorphisms in humans, it was hypothesised that
Cocker spaniels with IMHA would be more likely to
carry the DQB1*007:01 haplotype when compared to
healthy control animals; that polymorphisms in the ca-
nine CTLA4 promoter would be implicated in the devel-
opment of canine IMHA, and that combinations of DLA
type and polymorphisms in CTLA4 promoter might in-
crease overall susceptibility to IMHA in Cocker spaniels.
Results and discussion
Study population
Forty-six Cocker spaniels affected with IMHA were
identified from the Royal Veterinary College (RVC)
Canine Genetic Archive. Seventeen dogs were excluded
according to our defined criteria. Dogs were excluded
due to an equivocal diagnosis, presence of a concurrent
infectious condition, neoplasia, recent drug administra-
tion, pancytopenia, possible phosphofructokinase (PFK)
deficiency or pancreatitis. As a result, 29 Cocker spaniels
were included, three of which had evidence of concur-
rent immune mediated thrombocytopenia (Evan’s Syn-
drome). Fourteen (48 %) were male (six intact, eight
castrated) and 15 (52 %) were female (three intact, 12
neutered). The median age at the time of diagnosis was
7 years (range 9 months to 12 years).
Two hundred and seven Cocker spaniels were identi-
fied that were 9 years or older at the time of sample col-
lection and did not have a diagnosis of IMHA. One
hundred and forty-one dogs were subsequently excluded
based on presence of current or historical immune-
mediated or suspected immune-mediated disease and 3
dogs did not have relevant samples available. Sixty-three
suitable control dogs were therefore identified from the
RVC Canine Genetic Archive. Thirty-one (49 %) of the
dogs were male (14 intact, 17 castrated) and 32 (51 %)
of the dogs were female (5 intact and 27 neutered). The
median age of the control population was 10 years
(range 9 to 14 years). The medical conditions for which
they presented included neoplasia, intervertebral disc
disease, cardiac disease, vestibular disease, epilepsy, cata-
racts/lens luxation, fracture, chronic kidney disease, pyo-
metra, or polypoid cystitis. Several dogs had more than
one concurrent medical condition.
The age distribution of dogs with IMHA was similar
to that described in previous studies [4, 7, 10], support-
ing a predisposition in adult animals. This might reflect
the influence of cumulative environmental factors which
contribute to the development of IMHA in a geneticallysusceptible population. A female sex predilection for
IMHA in both humans and animals has been postulated
[6, 10, 16, 42], and neutered canines may also be predis-
posed [10, 42]. These findings were not supported in the
present study, where a balanced sex distribution was ob-
served in both the IMHA and control populations, and
the proportions of neutered animals were similar. It has
been suggested that androgens might be protective
against autoimmune diseases, and it is possible that the
genetic predisposition in Cocker spaniels negates any
protective effect provided by androgens.
Case-control association study of DLA-DQB1 alleles in
Cocker spaniels
Restricted variability of DLA haplotypes was identified
in Cocker spaniels [Tables 1 and 2]. The majority of dogs
had at least one copy of DQB1*007:01 (27/29 IMHA
cases; 93 % and 59/63 controls; 92 %). There was no sig-
nificant difference when the prevalence of homozygosity
for DLA-DQB1 (DQB1*007:01*007:01 or DQB1*020:01*
020:01) was compared between the IMHA and control
populations (p = 0.26). DQB1*020:01 was relatively more
prevalent in Cocker spaniels without IMHA (23/63; 37 %),
when compared with Cocker spaniels affected with IMHA
(6/29; 21 %), although there was no statistically significant
difference identified (p = 0.15). A new haplotype was iden-
tified in this study, which has not been documented previ-
ously. This was similar to DQB1*007:01, and has also been
recently identified in a population of Cocker spaniels at
the Centre for Integrated Genomic Medical Research in
Manchester (Kennedy L., personal communication). This
DLA haplotype appears specific to Cocker spaniels and
has been allocated the temporary name DQB1*lk007cs
[Fig. 1]. There was no difference in DQB1*lk007cs fre-
quency between Cocker spaniels with IMHA and the con-
trol population.
Table 2 DLA-DQB1 allele combinations in Cocker spaniels with
(cases) and without (controls) IMHA
DQB1* allele
combination
Cases
(n = 29
dogs)
Cases
(frequency)
Controls
(n = 63
dogs)
Controls
(frequency)
P value
007:01*002:01 1 0.034 1 0.016 0.533
007:01*007:01 14 0.483 23 0.365 0.361
007:01*lk007cs 2 0.069 5 0.080 1.000
007:01*012:01 1 0.034 3 0.048 1.000
007:01*013:03 2 0.069 2 0.032 0.588
007:01*020:01 5 0.172 18 0.286 0.306
007:01*020:02 0 0 2 0.032 1.000
007:01*021:01 1 0.034 2 0.032 1.000
007:01*08:01:1 1 0.034 2 0.032 1.000
012:01*020:01 0 0 2 0.032 1.000
020:01*013:02 0 0 1 0.016 1.000
020:01*020:01 1 0.034 1 0.016 0.533
020:01*020:02 0 0 1 0.016 1.000
020:02*023:01 1 0.034 0 0 0.315
Homozygous 15 0.517 24 0.381 0.260
Heterozygous 14 0.483 39 0.619 0.260
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[43]. The DLA-DQB1 locus was studied based on the
evidence that there is more variation when compared
with the DRB1 and DQA1 loci, and sequencing of DQB1
provided a method of distinguishing between the two
most commonly reported haplotypes in Cocker spaniels
(DLA-DRB1*006/DQA1*005/DQB*007 and DLA-DRB1*
006/DQA1*005/DQB*020). The data presented here were
similar to previous findings [27], whereby the DQB1*
007:01 allele occurred more frequently in IMHA affected
animals when compared to healthy individuals, and the
DQB1*020:01 allele was more frequent in the control
population, although no statistical information was pub-
lished on these data [27]. This should be interpreted with
caution until larger studies are undertaken.
Homozygosity for MHC-haplotypes has previously
been associated with higher risk of autoimmune disease
in Italian greyhounds [44], in chronic superficial keratitis
[45], in anal furunculosis in German shepherd dogs [26],Fig. 1 DQB1*lk007cs DNA sequencein SLE related disease complex [17] and hypoadrenocor-
ticism in Nova Scotia duck tolling retrievers, Labradors
and West Highland white terriers [18, 19], and necrotis-
ing meningoencephalitis (NME) in pugs [25]. The mo-
lecular mechanism behind the increased risk associated
with homozygosity, independent of haplotype, is not
fully understood, although some hypothesise that it is a
gene dosing effect, so having two copies of a risk allele
or haplotype increases the relative risk further [19]. A
recent study used to analyse associations with DLA type
in three canine autoimmune diseases utilised a different
methodology to target the extended DLA region [46].
An expanded DLA-wide SNP genotyping assay was de-
veloped which contradicted previous DLA associations in
weimeraners with hypertrophic osteodystrophy (HOD)
and Nova Scotia duck tolling retrievers with hypoadreno-
corticism, although supported previous DLA associations
found in NME in pugs [46]. Further investigation of DLA
variation in Cocker spaniels, and other breeds of dogs sus-
ceptible to IMHA, might be warranted, utilising this
methodology.
Case-control association study of CTLA4 promoter
polymorphisms in Cocker spaniels
Restricted variability in CTLA4 promoter SNPs, haplo-
types and genotypes was identified in Cocker spaniels
[Tables 3, 4 and 5]. Minor allele frequencies for pro-
moter SNPs were low, with no statistically significant
difference seen comparing cases and controls [Table 3].
All dogs had at least one copy of CTLA4 haplotype 8
(Fig. 3). Homozygosity for haplotype 8 was common in
Cocker spaniels with IMHA (27/29; 93 %) and in con-
trols (52/63; 81 %), with no statistically significant differ-
ence in prevalence between the two groups (p = 0.22).
CTLA4 promoter polymorphisms were not found to be
associated with susceptibility to IMHA in Cocker span-
iels in this study. Whilst all dogs had at least one copy
of haplotype 8, relatively more heterozygous dogs were
identified in the control population, which might suggest
that homozygosity for haplotype 8 could increase overall
susceptibility to IMHA in this breed. This finding was
not statistically significant, which possibly reflects the
relatively low power of the study, with a dominant haplo-
type in this breed. Therefore, a much larger number of
Table 3 CTLA4 promoter minor allele frequency in Cocker
spaniels with (cases) and without (controls) IMHA
Allele (SNP/INDEL) Minor
allele
Cases minor
allele frequency
Controls minor
allele frequency
P value
SNP 1 (A > G) A 0.017 0.063 0.276
SNP 2 (A > G) A 0.017 0.063 0.276
SNP 3 (G > A) A 0.000 0.008 1.000
SNP 4 (A > G) A 0.017 0.063 0.276
SNP 5 (A > G) A 0.017 0.063 0.276
SNP 6 (A > C) A 0.017 0.063 0.276
SNP 7 (G > A) G 0.017 0.063 0.276
SNP 8 (G > A) A 0.000 0.000 1.000
SNP 9 (G > A) A 0.000 0.016 1.000
SNP 10 (G > A) G 0.017 0.063 0.276
SNP 11 (C > G) G 0.000 0.000 1.000
SNP 12 (T > C) T 0.017 0.063 0.276
SNP 13 (C > T) T 0.017 0.016 1.000
SNP 14 (C > A) C 0.017 0.063 0.276
SNP 15 (C > T) C 0.017 0.063 0.276
SNP 16 (G > T) G 0.017 0.063 0.276
SNP 17 (T > C) C 0.000 0.000 1.000
SNP 18 (T > G) G 0.000 0.000 1.000
SNP 19 (A > G) A 0.017 0.063 0.276
SNP 20 (C > T) T 0.000 0.000 1.000
INDEL 1 + 0.000 0.000 1.000
INDEL 2 - 0.017 0.063 0.276
INDEL 3 + 0.034 0.079 0.345
Table 5 CTLA4 promoter genotype frequency in Cocker spaniels
with (cases) and without (controls) IMHA
Genotype Cases
(n = 29
dogs)
Cases
(frequency)
Controls
(n = 63
dogs)
Controls
(frequency)
P value
8/2 0 0.000 2 0.032 1.000
8/3 1 0.034 6 0.095 0.426
8/8 27 0.931 52 0.825 0.215
8/12 1 0.034 2 0.032 1.000
8/15 0 0.000 1 0.016 1.000
Homozygous 27 0.931 52 0.825 0.215
Heterozygous 2 0.069 11 0.175 0.215
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alter susceptibility for IMHA. In contrast, the presence of
haplotype 8 reduces the risk of the development of hypoa-
drenocorticism in Cocker spaniels [38], and a similar
trend might have been anticipated for IMHA in the same
breed, given the role of CTLA4 as a common susceptibil-
ity gene in several autoimmune diseases [47]. Further in-
vestigations in other susceptible breeds, such as the
English springer spaniel or miniature schnauzer are war-
ranted to better understand whether CTLA4 promoter
polymorphisms are implicated in susceptibility to IMHA.Table 4 CTLA4 promoter haplotype frequency in Cocker spaniels
with (cases) and without (controls) IMHA
Haplotype Cases
(2n = 58
haplotypes)
Cases
(frequency)
Controls
(2n = 126
haplotypes)
Controls
(frequency)
P value
2 0 0.000 2 0.159 1.000
3 1 0.017 6 0.048 0.436
8 56 0.966 115 0.913 0.234
12 1 0.017 2 0.159 1.000
15 0 0.000 1 0.008 1.000The promoter region of the CTLA4 gene was analysed
in this study, based on the evidence that very limited
genetic diversity has been identified in the coding region
in dogs, and there is a large amount of variability within
the promoter region [37]. The population of dogs inves-
tigated in the CTLA4 SNP discovery study included 93
dogs of ten breeds [37]. There were seven American
Cocker spaniels, but no English or working Cocker
spaniels. It is possible that there is variability within the
coding sequence that is breed specific and therefore has
not yet been identified. Further SNP discovery studies
are warranted in a larger pool of dogs to establish the
full extent of canine CTLA4 polymorphisms.
Relationship between DLA-DQB1 alleles and CTLA4
promoter polymorphisms in Cocker spaniels affected
with IMHA
Limited variability in DLA-DQB1 alleles and CTLA4
promoter haplotypes was identified in Cocker spaniels in
this study. There were considerable numbers of dogs
that were homozygous for both DLA-DQB allele and
CTLA4 promoter haplotype in both the IMHA (15/29;
52 %) and control populations (22/63; 35 %), with no
statistically significant difference between the two groups
(p = 0.17). The genes encoding DLA-DQB1 are on
chromosome 12 whereas the genes encoding CTLA4 are
situated on chromosome 37; DLA-DQB1 and CTLA4
are therefore not in linkage disequilibrium.
Limitations
There were several limitations of this study. Cocker
spaniels in both the case and control populations were
identified on the basis of owner reporting, rather than
Kennel Club registration; which may have introduced a
degree of bias, and the possibility of false associations.
Kennel Club registration details or pedigrees are rarely
available when animals present to a veterinary referral
hospital, and the population of Cocker Spaniels herein is
considered representative of the population seen in the
veterinary practice setting. It should be noted that the
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Mother Hospital for Animals is a large referral hospital,
accepting cases from a varied population of animals across
the south of England and whilst there remains no guaran-
tee that patients were not closely related, this was consid-
ered unlikely based on scrutiny of the case details. An
analysis of the recorded birth dates of included animals
suggested that there were no siblings, although birth dates
were recorded by the owner, and therefore this could
introduce a source of error. Population stratification is a
possibility, but considering the limited number of SNPs
assessed and their relatively low minor allele frequencies,
there was not enough variability in the dataset to be able
to perform robust analysis for stratification.
A control population of Cocker spaniels of 9 years old
or greater that did not have a history of immune-
mediated disease was selected; with the same limitations
regarding breed reporting and patient-relatedness appre-
ciated in this population. Klag (1993) and Reimer (1999)
demonstrated that IMHA can occur in dogs between 1
and 13 years, with a median of six years of age, and this
was also demonstrated in our case population. It is pos-
sible that a proportion of the control population might
have developed IMHA, or another autoimmune disease,
later in life. It is also possible that selection of an older
population of controls, compared with the cases might
have introduced bias as a consequence of temporal
changes in the genetic makeup of the breed, resulting
from a popular sire effect, although the relatively small
difference in ages between the two groups and the time
over which the samples were accrued make this unlikely
to have had a major effect. It is important to note that
the control population was selected from a clinical pa-
tient population, not healthy animals; background infor-
mation of the control animals was collected from
computer records at the Queen Mother Hospital for An-
imals (QMHA). This information was focussed on the
condition for which the animal was referred, and was
less likely to document previous history of an auto-
immune disease. The combination of these factors might
have increased the proportion of animals in the control
population with a susceptible genotype.
IMHA is a heterogeneous syndrome, and there might
be differences in the specific susceptibility genes that
contribute to the different phenotypes. Human auto-
immune haemolytic anaemia is commonly subdivided
according to the in vitro reactivity of the autoantibodies
involved, i.e. whether they cause auto-agglutination at
+4 °C or at +37 °C [16]. The in vitro reactivity com-
monly corresponds with the autoantibody type, with the
cold disease typically associated with IgM autoantibodies
and intravascular haemolysis, and the warm disease as-
sociated with IgG. Although less well characterised in
dogs, this has been documented [48], and it is possiblethat specific susceptibility haplotypes might have been
identified if the canine population in this study had been
subdivided based on the type of autoantibody involved.
This was not possible with the current patient cohort that
did not undergo Coombs’ testing. A prospective study,
with improved case phenotyping could be informative.
In this study, DLA*DQB1 was investigated alone, with-
out assessment of DRB or DQA. Complete DLA typing
would be preferable, although would be unlikely to re-
veal any clear associations in Cocker spaniels with and
without IMHA due to the limited DLA diversity in this
breed [43].
Conclusions
A genetic predisposition for IMHA is suspected, based
on breed and familial susceptibility. This study con-
firmed that the Cocker spaniel breed has limited genetic
diversity, demonstrated by the predominance of DLA al-
lele DQB1*007:01 and CTLA4 haplotype 8. This lack of
diversity within the breed at these two loci creates diffi-
culty in identifying genetic factors that predispose to
autoimmunity using the traditional case: control associ-
ation study approach. Given that Cocker spaniels are pre-
disposed to a number of autoimmune diseases including
IMHA [4], keratoconjunctivitis sicca [49], chronic pan-
creatitis [50] and hypothyroidism [23, 51], it is possible
that the breed as a whole is predisposed to autoimmunity,
but that other genes and environmental factors then influ-
ence disease progression.
We did not identify any association with IMHA and a
specific DLA-DQB1 type or CTLA4 promoter poly-
morphism in Cocker spaniels. It is likely that a larger
number of animals are required to unveil subtle differ-
ences in the genetic susceptibility for IMHA within this
breed. Continued study of IMHA in dogs presents op-
portunities for comparative and translational research
and might help develop a better understanding of the
pathophysiology of this complex disease.
Methods
Study population
EDTA blood samples were obtained from the genetic
archive of the RVC, University of London. Samples were
from Cocker spaniels that had been referred to the
QMHA between 1st February 2005 and 29th July 2013,
and had been archived following completion of diagnos-
tic testing with informed owner consent for their use in
clinical research, and with approval from the institu-
tional Ethics and Welfare Committee. Breeds were iden-
tified according to the owner report on admission of the
patient to the hospital; Kennel Club registration num-
bers were not available for review. Cocker spaniels were
included in the IMHA group population if they pre-
sented with a packed cell volume less than 30 %, and
Threlfall et al. Canine Genetics and Epidemiology  (2015) 2:8 Page 7 of 10also had evidence of immune-mediated destruction of
red blood cells (at least one of the following: spherocyto-
sis, positive in-saline agglutination, positive Coombs’
test, haemoglobinuria or hyperbilirubinaemia). Dogs were
excluded if they had any known history of exposure to a
primary trigger for IMHA, including any history of neo-
plasia, infection or recent drug therapy. Dogs were also
excluded if there was any indication of an erythrocyteFig. 2 Annotated canine CTLA4 promoter DNA sequence [37, 38]. SNPs an
TATA box and start codon are boxed. The start of the mRNA sequence (NM
SNPs are shown with the canine genome assembly allele (NC_006619.3) firenzyme deficiency, or if they had travelled outside of the
United Kingdom (UK), unless they had undergone sero-
logical examination for vector-borne diseases. Dogs had a
minimum of routine haematological and biochemical ana-
lyses, coupled with thoracic and abdominal imaging, to
exclude underlying diseases as far as possible.
A breed matched control population was identified by
examining clinical records of Cocker spaniels referred tod INDELs are labelled and primer-binding sites are underlined. The
_001003106.1) is shown in bold text at the 3ʹ end of the sequence.
st, followed by the variant allele
Threlfall et al. Canine Genetics and Epidemiology  (2015) 2:8 Page 8 of 10the QMHA during the same time period for investiga-
tion not associated with autoimmune disease. Control
animals were required to be nine years of age or older at
the time of sample collection. Dogs were excluded from
the control population if they had any known history of
immune-mediated disease.
DNA extraction and polymerase chain reaction (PCR)
Genomic DNA was extracted from EDTA blood using the
GenElute Blood Genomic Extraction Kit (Sigma-Aldrich,
UK) according to the manufacturer’s instructions. The
DNA was then used in PCR to amplify the DLA-DQB1
exon 2 and the CTLA4 promoter region (1.6 kb upstream
of exon 1), in separate reactions. Primers were synthesised
by Sigma- Aldrich (CTLA4 promoter sense: 5ʹ-TGCTC
CTCTGTGGCTATGTG-3ʹ and CTLA4 promoter anti-
sense: 5ʹ-TGAACACTGCTCCATAAAGC; DQB1/M13F
sense: 5ʹ- TGTAAAACGACGGCCAGTCTCACTGGCC
CGGCTGTCTC-3ʹ and DQB1 antisense: 5ʹ-CACCTCG
CCGCTGCAACGTG-3ʹ). The DLA-DQB1 sense primer
was tagged at the 5ʹ end with the M13F target sequence to
allow sequencing (Source Bioscience, UK) using the com-
pany stock primer (M13F 5ʹ-TGTAAAACGACGGCC
AGT-3ʹ). CTLA4 primers were designed by the Immun-
ology and Immunogenetics Laboratory at the Royal Veter-
inary College. PCR was performed in 25 μL reaction
volumes for DLA-DQB1 with 1 μL genomic DNA as tem-
plate and 2 μL of 20 pmol/μL final concentration DQB1-
specific primers, and 50 μL reaction volumes for theFig. 3 CTLA4 promoter haplotype assignment [37, 38]. SNPs are defined w
within the table), followed by the variant alleleCTLA4 promoter with 2 μL genomic DNA as template
and 4 μL of 20 pmol/μL total concentration CTLA4
promoter-specific primers. Each reaction contained Hi-Spec
additive (DLA-DQB1 5 μL; CTLA4 10 μL), ImmoBuffer
(DLA-DQB1 2.5 μL; CTLA4 5 μL), MgCl2 (DLA-DQB1
1.25 μL; CTLA4 2.5 μL; 2.5 mM final concentration),
deoxynucleotide triphosphates (DLA-DQB1 0.25 μL;
CTLA4 0.5 μL; 1 mM final concentration) and Immolase
DNA polymerase (DLA-DQB1 0.1 μL [1.25 U]; CTLA4
0.2 μL [2.5 IU]); (all Bioline, UK).
Thermocycling conditions consisted of an initial poly-
merase activation at 95 °C for 10 min, followed by 35 cy-
cles of 94 °C for 40 s (denaturation), 60 °C for 30 s
(annealing) and 72 °C for 1 min for DLA-DQB1 and
2 min for CTLA4 (elongation), with a final extension
step of 72 °C for 10 min (G-Storm GS1 Thermal Cycler,
Gene Technologies, UK).
The DLA-DQB1 PCR products were purified using the
GenElute PCR Clean-up Kit (Sigma-Aldrich, UK). CTLA4
promoter PCR products were electrophoresed on a 2 %
agarose/1*TBE gel containing 6 % Safe View Nucleic Acid
Stain (NBS Biologicals Ltd., UK) and using a 1 Kb molecu-
lar weight ladder (Hyperladder I, Bioline, UK). The gels
were visualised under UV light (ImageMaster VDS, Phar-
macia Biotech/GE Healthcare, UK). Gel extraction was
performed using the GenElute Gel Extraction Kit (Sigma-
Aldrich, UK) as per the manufacturer’s instructions.
The purified PCR product (DLA-DQB1) and the gel
extraction product (CTLA4 promoter) were submittedith the canine genome assembly allele (NC_006619.3) first (and shaded
Threlfall et al. Canine Genetics and Epidemiology  (2015) 2:8 Page 9 of 10for sequencing (Source Bioscience, UK). DLA-DQB1
analysis and assignment of alleles was performed using
SBT Engine version 2.17 (GenDx). DLA-DQB1 alleles
were assigned based on established nomenclature.¹ CTLA4
promoter chromatograms were analysed using BioEdit
Sequence Alignment Editor Software. Previously docu-
mented SNPs and indels were analysed and haplotypes
assigned for each dog [Figs. 2 and 3].
Statistical analyses
DLA-DQB1 and CTLA4 promoter allele, haplotype and
genotype frequencies were calculated for both groups
and compared between cases and controls using the
Fisher’s exact test. Associations were considered statisti-
cally significant if p < 0.05.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article (and its additional files).
Endnote
1See: http://www.ebi.ac.uk/ipd/mhc/dla/.
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